Foghorn Therapeutics Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Foghorn Therapeutics Inc. (FHTX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $41.14 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-11
- Foghorn Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $0.00.
- Foghorn Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $0.00.
- Foghorn Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-06-30 was $0.00.
- Foghorn Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- Foghorn Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $41.14M.
- Foghorn Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Foghorn Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $1.08M, a 620.00% increase from fiscal 2022.
- Foghorn Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $150.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $41.14M 10-K · filed 2026-03-11 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-11 | |||
| 2023-12-31 | $1.08M 10-K · filed 2025-03-06 | |||
| 2022-12-31 | $150.00K 10-K · filed 2024-03-07 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $0.00 derived: sum of 3 quarters · filed 2023-03-09 | $0.00 10-K · filed 2023-03-09 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | $0.00 derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $0.00 10-Q · filed 2021-08-10 | $0.00 derived: sum of 3 quarters · filed 2022-08-09 | $0.00 derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2022-08-09 | $0.00 derived: sum of 3 quarters · filed 2022-08-09 | $0.00 derived: sum of 4 quarters · filed 2022-08-09 |
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | $0.00 derived: sum of 2 quarters · filed 2022-08-09 | $0.00 derived: sum of 3 quarters · filed 2022-08-09 | $38.31M 10-K/A · filed 2022-08-09 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $38.31M 10-Q · filed 2021-11-09 | $38.31M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $38.31M 10-Q · filed 2021-08-10 | $38.31M derived: sum of 3 quarters · filed 2021-08-10 | |
| 2020-03-31 | $38.31M 10-Q · filed 2021-05-11 | $38.31M derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $271.00K 10-K · filed 2021-03-18 | ||
| 2019-09-30 | $271.00K 10-Q · filed 2020-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |